An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A person shared that they started 2024 weighing about 221 pounds and as of yesterday (Sep 20, 2026) weigh 133 pounds. They say they used Wegovy (a brand of the drug semaglutide) for weight loss, then stopped when their insurance stopped covering it and regained some weight. Recently their insurance began covering it again after a diagnosis of non-alcoholic fatty liver disease, and they restarted at a low dose. Semaglutide is the active drug in Wegovy and in other brands people may have heard of, like Ozempic. Simply put, it acts like a hormone your gut normally makes after you eat that tells your brain you’re full and also slows how quickly your stomach empties. Doctors use it for type 2 diabetes and, at higher doses, for helping people lose weight. It’s given by injection under the skin, and dosing is usually increased slowly so people tolerate it better. What this account shows is a single-person experience, not a controlled study. The person reports large weight loss over time, some regain after stopping the drug, and then a restart when coverage resumed. They mention being at about 160 pounds in January after the gap and now at 133 pounds after resuming treatment. Personal stories like this can signal that the drug helped, but they don’t prove cause-and-effect, don’t tell us how much of the change is diet, activity, other medications, or natural fluctuation, and can’t be generalized to everyone. Why this matters: semaglutide-based drugs have become a widely discussed option for people trying to lose significant weight. For someone with obesity-related health problems—like the person’s non-alcoholic fatty liver disease—weight loss can meaningfully improve health markers. Insurance coverage is also a huge practical barrier; this story underscores how access can determine whether someone can start or continue a treatment that might help them. Caveats and risks: individual anecdotes don’t replace clinical evidence. Semaglutide can cause side effects like nausea, diarrhea, constipation, and in rare cases more serious issues. Stopping the drug often leads to some weight regain if other lifestyle changes aren’t sustained. It’s also regulated—doctors prescribe it, and insurance rules vary. Anyone considering it should talk with their own doctor about benefits, risks, dosing, and cost, and should not assume they’ll see the same results as one person’s story. Bottom line: one person’s large weight changes line up with starting, stopping, and restarting semaglutide (Wegovy), but it’s an individual case and not proof the same will happen for others; medical advice and careful follow-up are essential.
Source: r/Semaglutide